LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-18
Case ID: NM_000179.3_c.4031_4039del_20261118_181423
Framework: ACMG/AMP 2015
Variant classification summary

NM_000179.3:c.4031_4039del

MSH6  · NP_000170.1:p.(Val1345_Ala1347del)  · NM_000179.3
GRCh37: chr2:48033946 ACTGTAGATG>A  ·  GRCh38: chr2:47806807 ACTGTAGATG>A
Gene: MSH6 Transcript: NM_000179.3
Final call
VUS
PM2 supporting
All criteria require review: For research and educational purposes only.
Gene
MSH6
Transcript
NM_000179.3
Protein
NP_000170.1:p.(Val1345_Ala1347del)
gnomAD AF
2.483250475542466e-06 (v4.1)
ClinVar
Uncertain significance
OncoKB
Unknown Oncogenic Effect
Interpretation summary
Generated evidence synthesis
1
PM2 supporting: gnomAD v4.1 total allele frequency is 2.48325e-06, below the VCEP threshold of 0.00002.
Final determination: Because PM2 supporting alone satisfies no pathogenic or benign rule in the MSH6 VCEP Version 2.0 framework, the variant remains a VUS.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: the variant is an in-frame 9-bp exon 10 deletion, whereas the VCEP PVS1 rule names nonsense, frameshift, splice, large-alteration, or RNA-confirmed aberration paths.
cspec vcep_pvs1_decisiontree_mmr vcep_vcep_pilot_variants_mmr pvs1_variant_assessment
PS1 N/A Not applicable: the variant is an in-frame three-residue deletion, whereas PS1 requires a predicted missense substitution or the same non-canonical splice nucleotide.
cspec
PS2 Not assessed Not assessed: no documented de novo result, parental testing, maternity/paternity confirmation, or VCEP de novo point assignment is available.
cspec
PS3 Not assessed Not assessed: no variant-specific functional assay result or calibrated functional odds were identified for the in-frame p.Val1345_Ala1347del deletion.
cspec vcep_functional_assay_svi_documentation_mmr vcep_functional_assay_flowchart PMID:30504929 PMID:31965077
PS4 N/A Not applicable: the MSH6 VCEP explicitly designates PS4 as Not Applicable, regardless of the available literature or case-control evidence.
cspec
PM1 N/A Not applicable: the MSH6 VCEP explicitly excludes PM1 because no recognized hotspot or domain-based PM1 route is approved for classification.
cspec vcep_mmr_functional_domains
PM2 Met Met at Supporting: gnomAD v4.1 total AF is 2.48325e-06, below the PM2 threshold of <0.00002 (<1 in 50,000 alleles).
cspec gnomad_v4
PM3 Not assessed Not assessed: no affected-proband observation with a pathogenic MSH6 variant in confirmed trans phase and no VCEP PM3 point total are documented.
cspec
PM4 N/A Not applicable: the MSH6 VCEP explicitly designates PM4 as Not Applicable for this framework.
cspec
PM5 N/A Not applicable: the target is an in-frame deletion, while PM5 requires a missense change and a different pathogenic or likely pathogenic missense change at the same residue.
cspec pm5_candidates
PM6 N/A Not applicable: the MSH6 VCEP specification explicitly marks PM6 as Not Applicable.
cspec
PP1 Not assessed Not assessed: no pedigree segregation data, informative meioses, or combined Bayes Likelihood Ratio is available for comparison with the VCEP thresholds.
cspec
PP2 N/A Not applicable: the MSH6 VCEP explicitly states that the low rate of benign missense variation PP2 rule does not apply.
cspec
PP3 N/A Not applicable: the variant is an in-frame deletion, outside PP3's missense or non-canonical splice-nucleotide scope, regardless of the available SpliceAI score.
cspec
PP4 Not assessed Not assessed: no patient-specific MSI, tumor-genome, or MMR-protein-expression result is available to compare with the VCEP's PP4 tumor thresholds.
cspec vcep_table_for_cmmrd_diagnosis vcep_vcep_pilot_variants_mmr
PP5 N/A Not applicable: the MSH6 VCEP explicitly designates PP5 as Not Applicable, and no variant-specific paper evidence overrides that rule.
cspec
BA1 Not met Not met: gnomAD v4.1 Grpmax FAF is 7.9e-07, below the BA1 threshold of ≥0.0022 (0.22%).
cspec gnomad_v4
BS1 Not met Not met: gnomAD v4.1 Grpmax FAF is 7.9e-07, below the BS1 interval beginning at ≥0.00022 (0.022%).
cspec gnomad_v4
BS2 Not assessed Not assessed: no qualifying in-trans co-occurrence, phase confirmation, cancer-age condition, or CMMRD-status documentation is available.
cspec
BS3 Not assessed Not assessed: no variant-specific proficient-function result or calibrated functional odds were identified for the in-frame p.Val1345_A1347del deletion.
cspec vcep_functional_assay_svi_documentation_mmr vcep_functional_assay_flowchart PMID:30504929 PMID:31965077
BS4 Not assessed Not assessed: no non-segregating carriers, informative pedigree, or combined Bayes Likelihood Ratio is available for comparison with the VCEP thresholds.
cspec
BP1 N/A Not applicable: the MSH6 VCEP excludes BP1, and the target is an in-frame deletion rather than a missense variant.
cspec
BP2 N/A Not applicable: the MSH6 VCEP specification explicitly marks BP2 as not applicable.
cspec
BP3 N/A Not applicable: the MSH6 VCEP explicitly designates BP3 as Not Applicable for this framework.
cspec
BP4 N/A Not applicable: the variant is an in-frame deletion, outside BP4's missense or intronic/synonymous scope, so SpliceAI 0.102 cannot establish BP4.
cspec
BP5 Not assessed Not assessed: no patient-specific tumor count or MSS, MMR-protein, BRAF V600E, or MLH1-methylation result is available for the BP5 requirements.
cspec
BP6 N/A Not applicable: the MSH6 VCEP explicitly designates BP6 as Not Applicable under its version 2.0 specification.
cspec
BP7 N/A Not applicable: the variant is an exonic in-frame deletion, not a synonymous or intronic variant at or beyond the BP7 -21/+7 boundary.
cspec
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.